A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Running, not enrolling · Phase 1

Conditions studied: Follicular Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma

In brief

This is a clinical trial to evaluate the feasibility and safety of giving tazemetostat followed by standard of care CAR T cell infusion in previously treated diffuse large b-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL). The investigators hypothesis is that this combination has the potential to significantly improve the ability of CART cells to recognize and kill lymphoma cells without a significant impact on safety. Participants will receive the tazemetostat pills before and after receiving their CAR T cell therapy, for up to 12 months after CAR T cell administration. Patients will be followed for up to 5 years.

Key facts

Study ID: NCT05934838
Run by: Weill Medical College of Cornell University
People needed: 15
Starts: 2023-10-04
Expected to finish: 2031-09-01
Last updated by the study team: 2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Confirmed diagnosis of DLBCL, FL, or MCL
Eligible to receive standard of care CAR T cells
Have received at least 1 prior therapies

You may not qualify if…

Active viral infection with HIV or hepatitis type B or C
Active, uncontrolled systemic fungal, bacterial or viral infection
Active treatment for another cancer
Pregnant or breastfeeding
Unable to take oral medication
Certain significant past medical history, such recent stroke, pulmonary embolism, myocardial infarction, congestive heart failure, uncontrolled hypertension, or certain arrhythmias

Where it is running

Weill Cornell Medicine/NewYork-Presbyterian Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.